Table 2.

Patient characteristics

N = 22
Median age at enrollment (range), years56.5 (39-74)
Location of primary
 Left side/rectal14 (64)
 Right7 (32)
 Unknown1 (5)
Gender, no. (%)
 Female10 (45)
 Male12 (55)
Race, no. (%)
 Non-hispanic caucasian16 (73)
 African American5 (23)
 Other1 (5)
ECOG, no. (%)
 08 (36)
 114 (64)
Median CEA at baseline107.0
Prior progression on irinotecan, no. (%)14 (64)
Median no. of prior therapies in metastatic setting (Range)2.5 (1–7)
Prior exposures, no. (%)
 5-FU22 (100)
 Oxaliplatin22 (100)
 Irinotecan22 (100)
 Bevacizumab19 (86)
 Cetuximab/panitumumab11 (50)
 Regorafenib5 (23)